Drug Profile
RGH 363
Alternative Names: RGH-363Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Gedeon Richter
- Class Antipsychotics
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Nov 2017 No recent reports of development identified for phase-I development in Schizophrenia in United Kingdom
- 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc